Merck Group, Springworks

Exclusive-Germany's Merck KGaA in talks to buy US biotech firm Springworks, sources say
Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics, according to people familiar with the matter.
Merck KGaA in Talks to Buy SpringWorks Therapeutics
Merck KGaA is in advanced talks to buy US cancer and rare diseases drugmaker SpringWorks Therapeutics Inc., according to a report from Reuters, citing people familiar with the matter.
Merck KGaA confirms ‘advanced’ talks to acquire SpringWorks
Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms
Merck KGaA Eyes Major U.S. Acquisition: Springworks Therapeutics on the Brink
German healthcare giant Merck KGaA is in advanced talks to acquire U.S.-based Springworks Therapeutics, known for cancer and rare disease treatments. The potential acquisition would enhance Merck's cancer treatment pipeline and rank among its largest recent deals.
Merck In Talks to Buy Cancer Drugmaker Springworks
After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.
SpringWorks jumps as Merck KGaA reportedly in talks to acquire company
Merck KGaA (MKGAY), the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker
FiercePharma4h
Merck KGaA sets its sights on acquisition of Ogsiveo-maker SpringWorks: Reuters
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
devdiscourse5h
Merck's Bold Move: Eyes on Springworks in Potential $4 Billion Acquisition
Merck KGaA is in advanced negotiations to acquire U.S.-based Springworks Therapeutics, a move that could rank among the largest pharma deals for Merck. This potential acquisition aims to boost Merck's ...
FierceBiotech8h
Kineta sells Genentech and Merck deals to investor ahead of TuHURA merger
Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...
Merck Is Suffering From a Classic Pharma Problem
Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.
Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook
Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
ATTENTION Merck & Co., Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck ...
Why Merck Stock Is Plummeting Today
Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...
Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...